Aspects of the present disclosure include bispecific molecules. The bispecific molecules comprise a cell-targeting moiety and a glycan-binding moiety. According to some embodiments, the cell-targeting moiety is a cancer cell-targeting moiety or an immune cell-targeting moiety. In certain embodiments, the glycan-binding moiety comprises the sialoglycan-binding domain of a lectin, non-limiting examples of which are sialic acid-binding immunoglobulin-like lectins (Siglecs). The bispecific molecules may take a variety of forms including heterodimeric molecules, fusion proteins, conjugates, and the like. Compositions, kits and methods of using the bifunctional molecules, e.g., for therapeutic purposes, are also provided.

Disclosed herein are immunoglobulin fusion proteins comprising an insulin therapeutic peptide and an immunoglobulin region that targets the insulin therapeutic peptide to the liver of an individual in need thereof. Further disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject, for example, diabetes and diabetes related conditions.

The finding that human immunodeficiency virus (HIV) envelope glycans bind CD62L (L-selectin) on central memory T cells is described. HIV infection is also shown to induce shedding of CD62L and this shedding is required for efficient release of HIV from infected cells. Methods of inhibiting HIV release from infected cells using inhibitors of CD62L sheddase are described. Methods of treating HIV infection with a CD62L sheddase, such as in combination with antiretroviral therapy, is also described.

Described herein are monoclonal antibodies that bind to VSIG-4 including antibodies that block the binding of VSIG-4 to SIGLEC-7, compositions including the monoclonal antibodies, and methods of making and using those antibodies and compositions.

The invention provides anti-variant Fc-region antibodies which specifically bind to an antibody that has the mutation P329G or the mutations P329G/L234A/L235A or the mutations I253A/H310A/H435A in the Fc-region, and methods of using the same.

Herein is reported an expression vector comprising an antibody light chain expression cassette, an antibody heavy chain expression cassette, and a selection marker expression cassette, wherein the expression cassettes are arranged unidirectional, and wherein the expression cassettes are arranged in the 5 to 3 sequence of antibody heavy chain expression cassette, antibody light chain expression cassette and selection marker expression cassette. Further are reported herein methods for the generation of antibody producing cells and the use of these cells for the recombinant production of antibodies.

Herein is reported a method for producing a human IgG4 or IgG1 isotype antibody comprising the following steps a) cultivating a cell comprising a nucleic acid encoding a human IgG4 or IgG1 isotype antibody, b) recovering the human IgG4 or IgG1 isotype antibody from the cell or the cultivation medium, c) contacting the human IgG4 or IgG1 isotype antibody with a protein A chromatography material, d) washing the protein A chromatography material with an aqueous solution comprising Histidine and Tris, e) recovering the human IgG4 or IgG1 isotype antibody from the protein A chromatography material
and thereby producing the human IgG4 or IgG1 isotype antibody.

The current invention reports a method for purifying an antibody by reducing the content of a host cell protein. The method employs a wash step with a low conductivity aqueous solution in an affinity chromatography.

Provided herein are methods for reducing corneal inflammation, reducing inflammatory cell (e.g., dendritic cell) recruitment to the cornea, and treating an corneal inflammatory disorder in a subject that include administering to the subject one or more of a MadCAM-1 antagonist, an 47 integrin antagonist, a L-selectin antagonist, and an E-selectin antagonist. Also provided are compositions containing one or more of a MadCAM-1 antagonist, an 47 integrin antagonist, a L-selectin antagonist, and an E-selectin antagonist, and kits containing these compositions.

The present disclosure relates to methods for treating pulmonary vaso-occlusion in a subject comprising administering to the subject a gasdermin-D inhibitor. In some examples. the disclosed methods are effective at treating subjects resistant to P-selectin-based therapy.